RNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Avidity Biosciences Inc (RNA) is not a strong buy for a beginner, long-term investor at this moment. While the company has shown significant revenue growth in the latest quarter, the financials remain negative with substantial net losses. Insider selling has increased significantly, and there are no clear positive trading signals or catalysts. The technical indicators are mixed, with a neutral RSI and a bearish MACD, suggesting no strong upward momentum. Options data also reflects a bearish sentiment with a high Put-Call ratio. Given the lack of positive catalysts and the investor's preference for long-term stability, holding off on this stock is the most prudent decision.
The stock's technical indicators are mixed. The MACD is negative and contracting, suggesting bearish momentum. RSI is neutral at 65.595, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are close to the current price, indicating limited immediate upside potential.
The company reported a significant revenue increase of 434.03% YoY in Q3 2025, indicating strong top-line growth.
Insiders are selling, with a 200.63% increase in selling activity over the last month.
No recent news or event-driven catalysts.
Options data shows bearish sentiment with a high Put-Call ratio.
Financials remain negative with a substantial net loss of -$174.44 million in Q3
Congress trading data shows no recent activity, indicating no influential support.
In Q3 2025, revenue increased by 434.03% YoY to $12.475 million. However, net income remains negative at -$174.44 million, albeit improving by 116.97% YoY. EPS also improved by 95.38% YoY to -1.27. Gross margin remains at 100%. While revenue growth is promising, the company is still far from profitability.
No data on analyst ratings or price target changes is provided.
